AR and prostate carcinoma: Three prostate cancer cell lines expressing either AR-FL with a T878A mutation (LNCaP), or expressing both AR-FL and multiple LBD-truncated AR-Vs including AR-V7 and AR-V9 that represent validated CRPC in vitro models (CWR22Rv1 and VCaP cells),17,52 were used to determine the potency of ITRI-90, ITRI-125 and ITRI-126.